A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

被引：57
|
作者：
Konopleva, Marina [1 ]
Pollyea, Daniel A. [2 ]
Potluri, Jalaja [3 ]
Chyla, Brenda J. [3 ]
Busman, Todd [3 ]
McKeegan, Evelyn [3 ]
Salem, Ahmed [3 ]
Zhu, Ming [3 ]
Ricker, Justin L. [3 ]
Blum, William [4 ]
DiNardo, Courtney D. [1 ]
Dunbar, Martin [3 ]
Kirby, Rachel [3 ]
Falotico, Nancy [3 ]
Leverson, Joel D. [3 ]
Humerickhouse, Rod A. [3 ]
Mabry, Mack [3 ]
Stone, Richard M. [5 ]
Kantarjian, Hagop M. [1 ]
Letai, Anthony G. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.118.118
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Seymour, John Francis
    Davids, Matthew Steven
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Miller, Thomas P.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Huang, David C. S.
    Darden, David E.
    Gressick, Lori A.
    Nolan, Cathy E.
    Yang, Jianning
    Busman, Todd A.
    Graham, Alison M.
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study
    Ma, Shuo
    Brander, Danielle M.
    Seymour, John F.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Davids, Matthew S.
    Anderson, Mary Ann
    Choi, Michael Y.
    Tam, Constantine S.
    Mason-Bright, Tanita
    Prine, Betty
    Munasinghe, Wijith
    Zhu, Ming
    Kim, Su Young
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2015, 126 (23)
  • [23] ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY
    Roberts, A. W.
    Ma, S.
    Kipps, T.
    Barrientos, J. C.
    Davids, M. S.
    Anderson, M. A.
    Tam, C.
    Mason-Bright, T.
    Rudersdorf, N. K.
    Yang, J.
    Munasinghe, W.
    Zhu, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Seymour, J. F.
    HAEMATOLOGICA, 2014, 99 : 249 - 249
  • [24] The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Flowers, Christopher R.
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan
    Reid, Erin
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Yang, Jianning
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod A.
    Kozloff, Mark
    BLOOD, 2014, 124 (21)
  • [25] Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
    Kumar, Shaji
    Vij, Ravi
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Facon, Thierry
    Moreau, Philippe
    Amiot, Martine
    Alzate, Stefanie
    Morris, Lura J.
    Ross, Jeremy A.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh K.
    Leverson, Joel
    Enschede, Sari H.
    Humerickhouse, Rod
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] INTERIM QUALITY OF LIFE RESULTS WITH VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DEL(17P) CHRONIC LYMPHOCYTIC LEUKEMIA
    Wierda, W.
    Cifaldi, M.
    Hsu, Li
    Cerri, E.
    Verdugo, M. E.
    HAEMATOLOGICA, 2016, 101 : 148 - 148
  • [27] Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Flinn, Ian
    Brunvand, Mark
    Dyer, Martin J. S.
    Hillman, Peter
    Jones, Jeffrey
    Lymp, James
    Elhamy, Mostafa
    Vosganian, Gregory
    Huang, Jane
    Kipps, Thomas J.
    BLOOD, 2014, 124 (21)
  • [28] Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles Andre
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Lymp, James
    Hilger, James
    Vosganian, Gregory
    Huang, Jane
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [29] ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.
    Ma, Shuo
    Seymour, John Francis
    Lanasa, Mark C.
    Kipps, Thomas J.
    Barrientos, Jacqueline Claudia
    Davids, Matthew Steven
    Mason-Bright, Tanita
    Rudersdorf, Nikita
    Yang, Jianning
    Munasinghe, Wijith
    Zhu, Ming
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Swinnen, Lode
    Kozloff, Mark
    Wang, Ding
    Reid, Erin
    Nastoupil, Loretta
    Fowler, Nathan
    Cordero, Jaclyn
    D'Amico, Diane
    Diehl, Susan
    Dunbar, Martin
    Zhu, Ming
    Wong, Shekman
    Enschede, Sari Heitner
    Chien, David
    Humerickhouse, Rod A.
    Flowers, Christopher
    BLOOD, 2015, 126 (23)
12345